vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and SILICON LABORATORIES INC. (SLAB). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $208.2M, roughly 1.2× SILICON LABORATORIES INC.). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 25.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-1.6M). Over the past eight quarters, SILICON LABORATORIES INC.'s revenue compounded faster (39.9% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Silicon Laboratories, Inc., commonly referred to as Silicon Labs, is a fabless global technology company that designs and manufactures semiconductors, other silicon devices and software, which it sells to electronics design engineers and manufacturers in Internet of Things (IoT) infrastructure worldwide.
ANIP vs SLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $208.2M |
| Net Profit | $27.5M | — |
| Gross Margin | — | 63.4% |
| Operating Margin | 14.1% | -1.6% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 25.2% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $208.2M | ||
| Q4 25 | $247.1M | $206.0M | ||
| Q3 25 | $227.8M | $192.8M | ||
| Q2 25 | $211.4M | $177.7M | ||
| Q1 25 | $197.1M | — | ||
| Q4 24 | $190.6M | $166.2M | ||
| Q3 24 | $148.3M | $166.4M | ||
| Q2 24 | $138.0M | $145.4M |
| Q1 26 | — | — | ||
| Q4 25 | $27.5M | $-9.9M | ||
| Q3 25 | $26.6M | $-21.8M | ||
| Q2 25 | $8.5M | — | ||
| Q1 25 | $15.7M | — | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-28.5M | ||
| Q2 24 | $-2.3M | $-82.2M |
| Q1 26 | — | 63.4% | ||
| Q4 25 | — | 57.8% | ||
| Q3 25 | — | 56.1% | ||
| Q2 25 | — | 55.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 54.3% | ||
| Q3 24 | — | 54.3% | ||
| Q2 24 | — | 52.7% |
| Q1 26 | — | -1.6% | ||
| Q4 25 | 14.1% | -6.0% | ||
| Q3 25 | 15.9% | -11.9% | ||
| Q2 25 | 6.6% | -18.1% | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | -17.2% | ||
| Q3 24 | -13.8% | -17.9% | ||
| Q2 24 | 3.7% | -33.0% |
| Q1 26 | — | — | ||
| Q4 25 | 11.1% | -4.8% | ||
| Q3 25 | 11.7% | -11.3% | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -17.1% | ||
| Q2 24 | -1.7% | -56.5% |
| Q1 26 | — | $-0.07 | ||
| Q4 25 | $1.14 | $-0.30 | ||
| Q3 25 | $1.13 | $-0.67 | ||
| Q2 25 | $0.36 | $-0.94 | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | $-0.72 | ||
| Q3 24 | $-1.27 | $-0.88 | ||
| Q2 24 | $-0.14 | $-2.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $443.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.1B |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $443.6M | ||
| Q4 25 | $285.6M | $439.0M | ||
| Q3 25 | $262.6M | $415.5M | ||
| Q2 25 | $217.8M | $424.8M | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | $382.2M | ||
| Q3 24 | $145.0M | $369.7M | ||
| Q2 24 | $240.1M | $339.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | — | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $1.1B | ||
| Q2 24 | $455.8M | $1.1B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $8.3M |
| Free Cash FlowOCF − Capex | $29.1M | $-1.6M |
| FCF MarginFCF / Revenue | 11.8% | -0.8% |
| Capex IntensityCapex / Revenue | 0.5% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.3M | ||
| Q4 25 | $30.4M | $34.3M | ||
| Q3 25 | $44.1M | $4.9M | ||
| Q2 25 | $75.8M | $48.1M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | $10.1M | ||
| Q3 24 | $12.5M | $31.6M | ||
| Q2 24 | $17.4M | $16.1M |
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $29.1M | $27.9M | ||
| Q3 25 | $38.0M | $-3.8M | ||
| Q2 25 | $71.8M | $43.3M | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $6.2M | ||
| Q3 24 | $7.7M | $29.4M | ||
| Q2 24 | $13.0M | $12.6M |
| Q1 26 | — | -0.8% | ||
| Q4 25 | 11.8% | 13.6% | ||
| Q3 25 | 16.7% | -2.0% | ||
| Q2 25 | 34.0% | 24.4% | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | 3.7% | ||
| Q3 24 | 5.2% | 17.7% | ||
| Q2 24 | 9.4% | 8.7% |
| Q1 26 | — | 4.8% | ||
| Q4 25 | 0.5% | 3.1% | ||
| Q3 25 | 2.7% | 4.5% | ||
| Q2 25 | 1.9% | 2.7% | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 3.2% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SLAB
| Sales Channel Through Intermediary | $157.5M | 76% |
| Sales Channel Directly To Consumer | $50.7M | 24% |
